What Are GLP-1 Clinical Trials & How Do I Join One?

<p><strong>What actually happens when you join a GLP-1 or obesity medication clinical trial? And could participating in one give you access to the next generation of obesity treatments before they reach the pharmacy?</strong></p><p>On this episode of <em>Weight &amp; Measure with Mike and Zach</em>, Mike Donnelly-Boylen and Zach Niemiec are joined by <strong>Dr. Domenica Rubino</strong>, founder and director of the Washington Center for Weight Management &amp; Research in Arlington, Virginia.</p><p>Dr. Rubino is an obesity medicine physician, endocrinologist, and longtime clinical researcher who has helped study obesity medications throughout the evolution of modern obesity care.</p><p>Together, we break down <strong>Clinical Trials 101</strong> from the perspective of the people actually volunteering to participate.</p><p>We discuss:</p><p>• What Phase 1, Phase 2, Phase 3 and Phase 4 clinical trials actually mean<br>• Why developing a medication can take 10–15 years<br>• What happens after you respond to a “Now Enrolling” clinical trial<br>• Screening, informed consent and randomization<br>• Why obesity medication trials still use placebo groups<br>• Your chances of receiving placebo versus an investigational medication<br>• What participating in a clinical trial costs<br>• Whether participants can be compensated for their time and travel<br>• What visits, testing and monitoring look like during a study<br>• What happens if you experience side effects or want to leave a trial<br>• Who is responsible for protecting clinical trial participants<br>• What happens when an investigational medication works but the trial ends<br>• Whether participants can continue receiving a medication after a study<br>• How to decide whether a clinical trial is right for you<br>• How to find legitimate obesity clinical trials on ClinicalTrials.gov<br>• Whether you can still join trials studying <strong>retatrutide, CagriSema and other next-generation obesity medications</strong><br>• The rapidly growing research into <strong>amylin-based medications, dual agonists and triple agonists</strong><br>• Why people who have undergone metabolic &amp; bariatric surgery may have fewer trial options, and why that may be changing<br>• Why you should never stop an effective obesity medication simply to qualify for a clinical trial</p><p>Dr. Rubino also shares an important warning for anyone eager to access the newest investigational obesity medications: <strong>a clinical trial isn&#39;t simply a way to get a new drug early.</strong> Participants need to understand the study, the possibility of receiving placebo, the potential risks and benefits, and whether participation makes sense for their individual situation.</p><p>Clinical trials are responsible for much of what we know about obesity treatment today. Behind every headline about a new medication are thousands of people who volunteered to help researchers answer those questions.</p><p>This episode is about understanding both <strong>the science and the people who make that science possible.</strong></p><p>🎙️ <strong>Guest:</strong> Dr. Domenica Rubino<br>🎙️ <strong>Hosts:</strong> Mike Donnelly-Boylen &amp; Zach Niemiec</p><p>Subscribe to <em>Weight &amp; Measure with Mike and Zach</em> on YouTube, Apple Podcasts, Spotify and Amazon Music.</p><p><strong>More Science. Less Stigma.</strong></p><p>#GLP1 #ClinicalTrials #Obesity #ObesityMedicine #Retatrutide #CagriSema #WeightLossMedications #ObesityTreatment #WeightAndMeasure</p><p></p>